Hosted on MSN7mon
Study finds adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence
The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only improved invasive-free survival in women with this type of early-stage ...
Novartis ribociclib recognized as Category 1 treatment by NCCN Guidelines
This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...
Medpage Today on MSN1mon
FDA Expands Approval of Ribociclib to Early Breast Cancer
The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...
Daily14d
Novartis' Ribociclib named as Category 1 Preferred Adjuvant Treatment for Breast Cancer in NCCN Guidelines
Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...
oncnursingnews16d
ASCO Recommends Abemaciclib for High-Risk HR+, HER2- Breast Cancer
A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.
MedPage Today1mon
Nagi El Saghir, MD, on What to Learn From the Final Results of the RIGHT Choice Trial
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recent clinical trial data suggested a new first-line ...
Daily12d
CDSCO Panel Approves Novartis Protocol Amendment Proposal to study Ribociclib
The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the ...
Yahoo Finance22d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
has adopted a positive opinion and recommended granting marketing authorization for Kisqali ® (ribociclib) for the adjuvant treatment of adults with hormone receptor-positive/human epidermal ...
Indiatimes1mon
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...
Pharmabiz21d
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...
Medscape23d
Medscape Medical News - FDA Approvals
Alert FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
The Financial Express16d
NCCN Guidelines recognises Novartis’ ribociclib as Category 1 preferred breast cancer adjuvant treatment
Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...